ERBB2 and breast carcinoma: Furthermore, CDK7 inhibitors can impede the activation of genes regulated by multiple HER2 inhibitor-resistant kinases, offering an alternative therapeutic approach to reverse acquired resistance in HER2-positive breast cancer (Sun et al., 2020).